Sunday, August 3, 2025

Latest

Curaleaf: Haywood Reiterates $22 Price Target, Names Firm A Top Pick For 2022

On December 28th, Curaleaf Holdings (CSE: CURA) announced that they have entered into a definitive agreement to acquire Bloom Dispensaries for roughly US$211 million in cash, with $50 million being paid at the closing date, and $50/$50/$60 million on the first, second and third anniversary of the closing date. The deal is expected to close in January of 2022 and Curaleaf expects it to be immediately accretive to adjusted EBITA.

Curaleaf currently has 15 analysts covering the stock with an average 12-month price target of C$24.80, or a 135% upside to the current stock price. Out of the 15 analysts, 5 have strong buy ratings, 9 have buy ratings and 1 analyst has a hold rating on the stock. The street high sits at C$31 from Stifel-GMP while the lowest 12-month price target comes in at C$20.

In Haywood Capital Markets’ note, they reiterate their C$22 12-month price target and buy rating, saying that this and the other recently announced acquisitions are an efficient use of proceeds. Bloom Dispensaries operates a 63,500 square foot cultivation and processing facility in Arizona, as well as several dispensaries. Haywood expects that the state of Arizona will do a combined $1.3 billion in sales for 2021.

Haywood says that Bloom is expected to do roughly $66 million in full-year revenue with adjusted EBITDA margins of >40%, so they have Bloom being acquired at a 3.2x 2021 and 8.0x 2021 revenue and adjusted EBITDA multiple. They also say that Arizona has continued to have a strong medical program while the adult-use program hit a new sales high in October. They believe that the market will grow faster than analysts’ expectations of $760 in adult-use sales by year four, as the state has done roughly $400 million this year alone.

Lastly, Haywood reiterates Curaleaf as their top pick in the cannabis sector, saying that it, “remains well-positioned with the largest state footprint.” They believe that this acquisition and the most recent debt financing will help Curaleaf expand its margins in 2022.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

AngloGold Buys Another Gold Junior! Augusta Gold Acquired For $197 Million

Another Gold Deal! Aris Mining Sells Assets To McFarlane

Royal Gold Goes Big | $3.5 Billion Sandstorm Acquisition

Recommended

Tsunami Warnings Spread As Largest Quake Since 2011 Hits Russia

Northern Superior Intersects 1.75 g/t Gold Over 65.0 Metres At Philibert

Related News

Hexo: Canaccord Cuts Price Target In Half To $1.00

On December 14th, Hexo Corp (TSX: HEXO) reported its fiscal first quarter 2022 results. The...

Saturday, December 18, 2021, 01:23:00 PM

BMO Raises Equinox Gold Price Target To $22 Following Premier Gold Transaction

Last Week, Equinox Gold Corp (TSX: EQX) announced the acquisition of Premier Gold Mines (TSX:...

Monday, December 21, 2020, 11:52:00 AM

Enphase Energy: BMO Calls For Margin Improvement On Increase Microinverter Sales

BMO Capital Markets’ recently hosted Enphase Energy’s (Nasdaq: ENPH) Head of Investor Relations, Karen Sagot...

Sunday, October 16, 2022, 03:16:00 PM

Valens: Haywood Reiterates Price Target, Raises Estimates

On June 1st, The Valens Company (TSX: VLNS) announced that they closed their C$40 million...

Sunday, June 6, 2021, 01:38:00 PM

Organigram: Consensus Price Target Falls To $3.55

On November 23rd, Organigram Holdings (TSX: OGI) announced its fourth quarter fiscal 2021 results. The...

Sunday, November 28, 2021, 01:18:00 PM